Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies’ Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders
Authors:
Open Access
- 1 October 2024
- journal article
- research article
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 13, 525-539
Abstract
Lack of response to immunotherapies poses a significant challenge in treating immune-mediated disorders and cancers. While the mechanisms associated with poor responsiveness are not well defined and change between and among subjects, the current methods for overcoming the loss of response are insufficient. The Constrained Disorder Principle (CDP) explains biological systems based on their inherent variability, bounded by dynamic boundaries that change in response to internal and external perturbations. Inter and intra-subject variability characterize the immune system, making it difficult to provide a single therapeutic regimen to all patients and even the same patients over time. The dynamicity of the immune variability is also a significant challenge for personalizing immunotherapies. The CDP-based second-generation artificial intelligence system is an outcome-based dynamic platform that incorporates personalized variability signatures into the therapeutic regimen and may provide methods for improving the response and overcoming the loss of response to treatments. The signatures of immune variability may also offer a method for identifying new biomarkers for early diagnosis, monitoring immune-related disorders, and evaluating the response to treatments.Keywords
This publication has 175 references indexed in Scilit:
- Revising immune cell coordination: Origins and importance of single‐cell variationEuropean Journal of Immunology, 2022
- Enhancing the plasticity, proper function and efficient use of energy of the Sun, genes and microtubules using variabilityClinical and Translational Discovery, 2022
- Profiling cellular heterogeneity in asthma with single cell multiparameter CyTOFJournal of Leukocyte Biology, 2020
- Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2020
- Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapyPharmacology Research & Perspectives, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Randomness in microtubule dynamics: an error that requires correction or an inherent plasticity required for normal cellular function?Cell Biology International, 2019
- Microtubules: From understanding their dynamics to using them as potential therapeutic targetsJournal of Cellular Physiology, 2018
- Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF DrugJAMA, 2016
- Aging of the immune system: Focus on inflammation and vaccinationEuropean Journal of Immunology, 2016